Eczema patients may get relief with fewer shots

NCT ID NCT06004986

Recruiting now Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study looks at whether adults with controlled atopic eczema can safely extend the time between dupilumab injections from every 2 weeks to every 3 or 4 weeks. About 216 participants will be randomly assigned to one of three dosing schedules. Researchers will compare eczema severity and quality of life to see if less frequent dosing is just as effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amsterdam University Medical Centers
RECRUITING

Amsterdam, North Holland, 1105 AZ, Netherlands

Contact
Erasmus Medical Center
NOT_YET_RECRUITING

Rotterdam, South Holland, 3015 GD, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS ATOPIC DERMATITIS / ECZEMA